Hong Kong – July 8, 2021 – Cooley advised biotechnology company Keymed Biosciences on its HK$3.1 billion (US$400 million) initial public offering on the Hong Kong Stock Exchange. Partners Yiming Liu, Michael Yu and Will Cai led the Cooley team advising Keymed Biosciences on its public debut, which also included Yiying Wang, Xiaoyu Xu, Kaiting Yang, Henry Wang, Bridget Wang and Iris Yang.
“Our global capital markets practice has long solidified Cooley as a leader in key IPO centers around the world, and now we can say the same for Hong Kong,” said Cai, who is head of Cooley's Asia capital markets practice. “We are excited to continue this momentum through the remainder of 2021 and beyond.”
Morgan Stanley, China International Capital Corporation and Huatai acted as the joint sponsors and the joint global coordinators on the offering.
Keymed Biosciences is a China-based biotechnology company focused on in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. Founded in 2016, the company has built up a pipeline of nine investigational new drug-enabling and clinical-stage drug candidates, including five clinical-stage candidates that are each among the first three domestically-developed for their target or in their class to have obtained IND approval in China and/or the US.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,200 lawyers across 17 offices in the United States, Asia and Europe.